文献速递脑血管病

急性缺血性卒中延迟治疗窗内溶栓:系统综述与Meta分析更新

Thrombolysis in the Delayed Treatment Window for Acute Ischemic Stroke: Updated Systematic Review and Meta-Analysis
RSS 订阅 · Stroke

结果显示溶栓改善90天极佳功能结局和功能独立,增加症状性颅内出血风险但不显著影响90天死亡率,支持基于组织窗而非严格时间窗的治疗策略。

要点

  • 影像筛选下超4.5小时溶栓改善90天极佳功能结局(RR 1.22,95%CI 1.16–1.29)。
  • 溶栓增加症状性颅内出血风险(RR 2.58,95%CI 1.58–4.22),但90天死亡率无显著差异。
  • 阿替普酶和替奈普酶均贡献上述获益,支持组织窗指导的溶栓决策。

核心结论

  • 经先进影像筛选、发病超过4.5小时或醒后/未知发病的急性缺血性卒中患者,静脉溶栓改善功能结局且不增加死亡率。
  • 结果支持基于组织窗而非严格时间窗的治疗策略。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA指南,检索PubMed、Embase和Cochrane Central至2026年2月。

主要发现

  • 静脉溶栓改善90天极佳功能结局(mRS 0–1;RR 1.22,95%CI 1.16–1.29)。
  • 静脉溶栓改善功能独立(mRS 0–2;RR 1.12,95%CI 1.06–1.18)。
  • 阿替普酶和替奈普酶均贡献上述获益。
  • 溶栓增加症状性颅内出血风险(RR 2.58,95%CI 1.58–4.22)。
  • 90天死亡率无显著影响(RR 1.15,95%CI 0.97–1.35)。

关键数值与推荐

  • 主要结局为90天极佳功能结局(mRS 0–1)。
  • 次要结局包括功能独立(mRS 0–2)、症状性颅内出血和90天死亡率。

临床怎么用

  • 对发病超过4.5小时或醒后/未知发病的急性缺血性卒中患者,可依据多模影像筛选可挽救脑组织后考虑静脉溶栓。
  • 溶栓决策需权衡功能获益与症状性颅内出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, Ahead of Print. BACKGROUND:Intravenous thrombolysis is a standard treatment for acute ischemic stroke but has traditionally been limited to 4.5 hours after symptom onset. This time-based restriction may exclude patients with salvageable brain tissue, especially those with wake-up or unknown-onset strokes. Multimodal imaging allows for the identification of viable penumbra beyond traditional treatment windows. This study compiles randomized evidence evaluating intravenous thrombolysis in imaging-selected patients treated after 4.5 hours.METHODS:We conducted a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Embase, and Cochrane Central were searched through February 2026 for randomized trials comparing intravenous thrombolysis (alteplase or tenecteplase) with best medical therapy in patients presenting beyond 4.5 hours or with wake-up/unknown-onset stroke selected by imaging. The primary outcome was excellent functional outcome at 90 days (modified Rankin Scale score 0–1). Secondary outcomes included functional independence (modified Rankin Scale score 0–2), symptomatic intracranial hemorrhage, and 90-day mortality.RESULTS:Fourteen trials involving 4192 participants were analyzed. Intravenous thrombolysis improved excellent functional outcomes (modified Rankin Scale score 0–1; risk ratio, 1.22 [95% CI, 1.16–1.29]) and functional independence (modified Rankin Scale score 0–2; risk ratio, 1.12 [95% CI, 1.06–1.18]). Both alteplase and tenecteplase contributed to these benefits. Thrombolysis increased the risk of symptomatic intracranial hemorrhage (risk ratio, 2.58 [95% CI, 1.58–4.22]) but did not significantly affect 90-day mortality (risk ratio, 1.15 [95% CI, 0.97–1.35]).CONCLUSIONS:In patients selected using advanced imaging, intravenous thrombolysis performed after 4.5 hours improves functional outcomes without increasing mortality, supporting a tissue-based rather than strictly time-based approach to treating acute ischemic stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Stroke:Thrombolysis in the Delayed Treatment Window for Acute Ischemic Stroke: Updated Systematic Review and Meta-Analysis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。